HC Wainwright Brokers Reduce Earnings Estimates for Rezolute

Rezolute, Inc. (NASDAQ:RZLT) – Equities research analysts at HC Wainwright decreased their FY2026 EPS estimates for Rezolute in a research report issued on Wednesday, May 13th. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.67) per share for the year, down from their prior estimate of ($0.57). The consensus estimate for Rezolute’s current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Rezolute’s Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.09) EPS, FY2027 earnings at ($0.45) EPS and FY2028 earnings at ($0.33) EPS.

RZLT has been the topic of a number of other reports. Maxim Group upped their target price on shares of Rezolute from $4.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rezolute in a research report on Tuesday, April 21st. Finally, Wedbush upgraded shares of Rezolute from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $2.00 to $5.00 in a research report on Wednesday, March 25th. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.75.

Rezolute Trading Up 2.1%

Shares of RZLT stock opened at $3.40 on Friday. Rezolute has a 1 year low of $1.07 and a 1 year high of $11.46. The firm’s 50 day moving average is $3.14 and its 200-day moving average is $4.54. The firm has a market capitalization of $327.39 million, a price-to-earnings ratio of -4.15 and a beta of 0.66.

Rezolute (NASDAQ:RZLT) last announced its earnings results on Tuesday, May 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in Rezolute during the 2nd quarter worth approximately $25,000. Russell Investments Group Ltd. bought a new position in Rezolute during the 3rd quarter worth approximately $61,000. Legal & General Group Plc bought a new position in Rezolute during the 2nd quarter worth approximately $32,000. China Universal Asset Management Co. Ltd. bought a new position in Rezolute during the 3rd quarter worth approximately $94,000. Finally, Raymond James Financial Inc. bought a new position in Rezolute during the 2nd quarter worth approximately $46,000. Institutional investors own 82.97% of the company’s stock.

Key Rezolute News

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: HC Wainwright raised near-term earnings expectations for Rezolute’s Q1 2027, Q2 2027, and FY2027 results, signaling some improvement in the outlook for the company’s profitability trajectory. Rezolute analyst estimate updates
• Positive Sentiment: The firm also lifted its FY2028 forecast, which can support sentiment by suggesting longer-term earnings potential remains intact even after recent revisions. Rezolute analyst estimate updates
• Neutral Sentiment: The analyst still expects Rezolute to remain unprofitable over the next several years, with earnings forecasts largely in negative territory and the current full-year consensus at $(0.68) per share. Rezolute analyst estimate updates
• Negative Sentiment: HC Wainwright cut several estimates, including Q4 2026, Q3 2027, and FY2026, which could temper enthusiasm because it suggests some near-term pressure on earnings expectations. Rezolute analyst estimate updates

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.